GlobeNewswire·Sep 16, 2026, 8:46 AM ET

NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

NeOnc Technologies Holdings (NASDAQ: NTHI) executives purchased approximately $629,000 worth of shares in the open market using personal funds following positive Phase 2a results for NEO100.
CEO Amir F. Heshmatpour bought 35,000 shares on September 15 for $115,400, bringing his post-results total to 111,000 shares valued at $418,700.
CMO Thomas C. Chen purchased 49,016 shares for $210,000, resulting in a combined executive purchase of 160,016 shares.
The company announced its NEO100-01 Phase 2a study met its primary endpoint with a six-month progression-free survival rate of 48.9%, surpassing the 20% benchmark.
Clinical data for NEO100 showed a p-value of 0.0047 & a median overall survival of 26.09 months for central nervous system cancers.
NeOnc is developing its platform to address the blood-brain barrier, with a second candidate, NEO212, having completed Phase 1 dose escalation.
The company recently secured $15 million through a registered direct offering to fund its clinical programs.
Executive Chairman Heshmatpour stated his total personal investment in the company now exceeds $1.5 million over the past year.